H.C. Wainwright Keeps Their Buy Rating on Harpoon Therapeutics (HARP)

In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Harpoon Therapeutics (HARP), with a price target of $31.00. The company’s shares closed last Friday at $15.86.

According to TipRanks.com, Ramakanth is a 5-star analyst with an average return of 33.7% and a 51.7% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals, Corvus Pharmaceuticals, and Trillium Therapeutics.

Currently, the analyst consensus on Harpoon Therapeutics is a Strong Buy with an average price target of $33.71, a 77.4% upside from current levels. In a report issued on May 28, Cantor Fitzgerald also initiated coverage with a Buy rating on the stock with a $40.00 price target.

See today’s analyst top recommended stocks >>

Based on Harpoon Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $9.01 million and GAAP net loss of $61.72 million. In comparison, last year the company earned revenue of $3.3 million and had a GAAP net loss of $12.55 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company, which develops a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. It offers Tri-specific T cell Activating Construct (TriTACs) that focuses on the treatment of solid tumors and hematologic malignancies. The company founded by Patrick A. Baeuerle, Luke B. Evnin, and Jeanmarie Guenot on March 19, 2015 and is headquartered in South San Francisco, CA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts